Related Experiment Video
Updated: May 13, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Simultaneous quantitation of tigecycline, meropenem, polymyxin B in plasma, and protein-binding analysis in HSCT
Yan Gong1, Weijing Gong1, Junmiao Chen2
1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Aims:
To develop a UPLC-MS/MS method for quantifying tigecycline (TIG), meropenem (MER), polymyxin B1 (PB1), and PB2 in human plasma, and analyze their unbound fractions and influencing factors in HSCT patients.
Methods:
Plasma samples from HSCT patients were analyzed using the developed UPLC-MS/MS technique.
Results:
The method showed high accuracy, precision, and stability. Protein binding rates were 82.4% for TIG, 83.7%-79.3% for PB1, and 86.7%-82.6% for PB2, with lower binding at trough vs. peak concentrations.
Conclusions:
Preliminary analysis suggests that BMI and serum albumin may influence PB1/PB2 binding in CRE-infected HSCT patients though larger cohorts are needed for confirmation. (clinical trial registration # 2021-0938-01).
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Related Concept Videos
Restorative Care
Continuing Care
Nursing Process for Patient and Caregiver Teaching I: Assessment and Diagnosis
It is critical to determine the patient's learning needs during the assessment. Determination of learning needs compounds data from the...
Documentation in Long-Term and Home Healthcare Setting
Long-Term Care Facilities
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia
The progression of dementia is generally gradual.